KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TherapeuticsMD (TXMD) Cost of Revenue (2016 - 2023)

TherapeuticsMD (TXMD) has disclosed Cost of Revenue for 13 consecutive years, with $106000.0 as the latest value for Q3 2023.

  • For the quarter ending Q3 2023, Cost of Revenue fell 99.45% year-over-year to $106000.0, compared with a TTM value of $106000.0 through Dec 2023, down 99.47%, and an annual FY2022 reading of $1.4 million, changed 0.36% over the prior year.
  • Cost of Revenue was $106000.0 for Q3 2023 at TherapeuticsMD, down from $19.1 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $110.8 million in Q4 2019 and bottomed at -$84.8 million in Q4 2021.
  • Average Cost of Revenue over 5 years is $7.7 million, with a median of $2.1 million recorded in 2019.
  • The sharpest move saw Cost of Revenue surged 11551.33% in 2019, then plummeted 527.48% in 2021.
  • Year by year, Cost of Revenue stood at $110.8 million in 2019, then crashed by 112.2% to -$13.5 million in 2020, then tumbled by 527.48% to -$84.8 million in 2021, then skyrocketed by 122.56% to $19.1 million in 2022, then tumbled by 99.45% to $106000.0 in 2023.
  • Business Quant data shows Cost of Revenue for TXMD at $106000.0 in Q3 2023, $19.1 million in Q3 2022, and $348000.0 in Q2 2022.